Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 11:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer, Prostate Clear all

Conditions: Decision Support Systems, Clinical, Prostate Cancer
Interventions: Decision Support Intervention (DSI); Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: Palo Alto, California • San Francisco, California • Sartell, Minnesota + 1 more

Conditions: Prostate Cancer
Interventions: VDC2008, Cyclophosphamide; Biological · Drug
Lead sponsor: Bostwick Laboratories; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Ventura, California

Conditions: Prostate Cancer
Interventions: Soccer; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 79 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Prostate Cancer
Interventions: lovastatin; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 3
States / cities: Richmond, Virginia

Conditions: Prostate Cancer
Interventions: ExoDx Prostate; Diagnostic Test
Lead sponsor: Exosome Diagnostics, Inc.; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Baltimore, Maryland • Voorhees Township, New Jersey

Conditions: Prostate Cancer
Interventions: Mindfulness-based Intervention, Usual Care; Behavioral
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: Leuprolide, Goserelin, Sunitinib Malate, Casodex, Radiation Therapy (RT); Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ovarian Cancer, Breast Cancer, Prostate Cancer
Interventions: LY2606368; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: lycopene; Dietary Supplement
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 45 Years · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Cancer
Interventions: bicalutamide, estramustine, etoposide, flutamide, goserelin, leuprolide, nilutamide, paclitaxel; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 91
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more

Conditions: Prostatic Neoplasms
Interventions: Docetaxel (TAXOTERE®) Chemotherapy, Leuprolide acetate ( ELIGARD®) Hormonal Therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Prostate Cancer
Interventions: Abiraterone - Usual, Abiraterone - Study; Drug
Lead sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair; Industry
Eligibility: 22 Years to 75 Years · Male only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: C11-Sodium Acetate; Drug
Lead sponsor: Phoenix Molecular Imaging; Other
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Prostate Cancer
Interventions: Panobinostat; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 5
States / cities: Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more

Conditions: BRCA1 Mutation, BRCA2 Mutation
Interventions: Web + Streamlined Telephone Genetic Information; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • Danville, Pennsylvania

Conditions: Prostate Cancer Patients
Interventions: 11C-Acetate; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: ketoconazole, therapeutic hydrocortisone, Withdrawal of antiandrogen therapy; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Up to 120 Years · Male only
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2009
U.S. locations: 2
States / cities: San Francisco, California • Minneapolis, Minnesota

Conditions: Prostate Adenocarcinoma
Interventions: Computed Tomography, Fluciclovine F18, Gallium Ga68-labeled PSMA-11, Positron Emission Tomography; Procedure · Drug · Radiation
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Prostate Cancer
Interventions: SBRT; Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Ovarian Carcinoma, Ovarian Germ Cell Tumor
Interventions: Laboratory Biomarker Analysis, Screening Questionnaire Administration, Ultrasound Imaging; Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 55 Years to 74 Years · Female only
Enrollment: 78,216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostatic Neoplasms
Interventions: PROSTVAC; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions: axitinib, therapeutic conventional surgery, enzyme-linked immunosorbent assay, laboratory biomarker analysis; Drug · Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Duarte, California

Conditions: Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Sexual Dysfunction and Infertility, Sexuality and Reproductive Issues
Interventions: communication intervention, counseling intervention, questionnaire administration, psychosocial assessment and care; Other · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Search by objective public record fields.

Pioneering Advances in Care and Education (PACE)

Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer

Soccer Intervention in Prostate Cancer Survivors

Study of Effectiveness of Lovastatin to Prevent Radiation-Induced Rectal Injury

ExoDx Prostate Evaluation in Prior Negative Prostate Biopsy Setting

Testing the Effect of Mindfulness for Prostatectomy Outcomes

Changes in Brown Adipose Tissue Activity In Men Receiving Androgen Deprivation Therapy for Prostate Cancer

Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

Lycopene in Preventing Prostate Cancer in Healthy Participants

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy

Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms

C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma

Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer

Genetic Education in BRCA Families

C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate Cancer

Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer

Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes

SBRT for Oligometastatic Castration-Refractory Prostate Cancer

Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)

A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate

Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer

Communication and Intimacy-Enhancing Therapy for Men With Early Stage Prostate Cancer and Their Partners